| Proposed Ticker: INGX | 1505 O'Brien Drive | |
| Exchange: NASDAQ-National Market | Menlo Park, California 94025 | |
| Industry: Manufacturing | (415) 617-9570 |
| All share information is proposed | ||||
| Type of Shares: | Common Shares | Filing Date: | 7/3/96 | |
| U.S. Shares Filed: | 1,850,000 | Filing Range: | $8.50 - $9.50 | |
| Non-U.S. Shares Filed: | 0 | Offering Amount: | $16,650,000 | |
| Primary Shares: | 1,850,000 | Expenses: | - | |
| Secondary Shares: | 0 | Shs Out After: | 4,844,391 | |
| Spin out parent firm: | Titan Pharmaceuticals, Inc. | |||
| Manager | Tier | Phone |
| Kaufman Brothers L.P. | Lead Manager | (800) 807-8723 |
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 3/31/96 | 3/31/95 | 3/31/96 | ||
| Revenue: | $0.14 | $0.05 | $0.00 | Assets: | $4.18 |
| Net Income: | -$5.00 | -$0.90 | -$1.09 | Liabilities: | $10.30 |
| EPS: | -$1.72 | -$0.29 | Equity: | -$6.11 | |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company is a biopharmaceutical company engaged in the development of proprietary gene-based therapies and the application of functional genetics to pharmaceutical discovery. The company's initial commercial strategy is top develop gene therapy products for the oncology market. The company currently is sponsoring a Phase 1/2 clinical trial of MDRx1, a gene therapy product aimed at limiting the destruction by cytotoxic drugs of normal blood-forming cells in the bone marrow of cancer patients undergoing chemotherapy. The company believes that MDRx1 will permit the administration of increased doses of cytotoxic drugs to cancer patients, resulting in the increased efficacy of chemotherapy. The company also is developing a gene therapy product based on RB94, a modified form of RB, a tumor supressor gene. This product is intended to cause the regression of localized, malignant cancers. In addition, the company is building a new, proprietary genomics technology, the GSX System, which identifies genes based on their function and is designed to pinpoint key steps in a disease pathway for therapeutic intervention. The company believes that the GSX System may be used to develop treatments for a wide range of diseases through the discovery of both gene therapy products and small molecule drugs. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used for repayment of indebtedness, research and development, working capital and other general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.